FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Published
09 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$4.00
89.8% undervalued intrinsic discount
15 Aug
US$0.41
Loading
1Y
-60.1%
7D
-3.7%

Author's Valuation

US$4.0

89.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 69%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 139%

AnalystConsensusTarget has increased revenue growth from 93.5% to 129.7%, increased future PE multiple from 104.5x to 148.3x and decreased shares outstanding growth rate from 0.0% to 0.0%.